There’s no pleasing some people. Abbott (NYSE:ABT) shares were down on Wall Street today, despite the health care products giant reporting strong second-quarter sales and earnings figures — including a nearly 100 percent top-line surge for its coronary stents business.
The Abbott Park, Ill.-based conglomerate reported profits of $1.94 billion, or $1.23 per diluted share, on sales of $9.62 billion for the three months ended June 30. That’s a revenue increase of 9.0 percent and a bottom-line surge of 50.4 percent, compared with the $1.29 billion profit (83 cents diluted EPS) on sales of $8.83 billion during the same period last year.
Excluding some one-time items associated with acquisitions, "cost reduction initiatives," a writedown of intangible assets and a tax gain from 2010, net earnings were $1.77 billion, or $1.12 per diluted share, up 12.0 percent and 10.9 percent, respectively.
The quarter also featured a strong performance by Abbott’s coronary stent unit. Total sales were up 96.8 percent to $1.05 billion; U.S. sales rose 71.3 percent to $478 million and international sales rose 124.8 percent to $571 million.
"Abbott is well-positioned for a strong second half of the year as we remain on track for double-digit EPS growth in 2011," chairman & CEO Miles White said in prepared remarks. "We’re also pleased with our growth in emerging markets, as well as the progress of our broad-based pipeline, including several new product approvals, regulatory submissions and clinical trial initiations."
The company boosted its diluted EPS guidance for the fully year to between $4.58 and $4.68, up from $4.54 to $4.64, excluding special items.
That failed to impress The Street, where ABT shares closed down about 1 percent to $52.40.
MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup, where we collect each quarter’s reports.
Here’s a quick rundown of a few releases over the past couple days:
U.S. CRM sales flat for St. Jude Medical in Q2
St. Jude Medical (NYSE:STJ) reported flat CRM sales in the three months ended July 2 compared to the same period last year, with U.S. sales dropping 2 percent to $401 million, compared to $409 million last year.
“U.S. CRM sales fell into a pot hole,” Dan Starks, president & CEO of St. Jude Medical, said in a conference call with investors Wednesday.
Overall, St. Jude reported a $241 million profit on about $1.44 billion in sales during the quarter, a 5.5 percent drop from the $254 million profit the company made on $1.31 million during the same period last year.
Included in the company’s earnings was a $32 million restructuring charge related to the shuttering of a Swedish manufacturing facility for CRM products in favor of more affordable locations in Puerto Rico and Malaysia, which will result in the loss of about 450 workers.
Stryker slips on Q2 profit slide
Stryker Corp. (NYSE:SYK) reported a 3 percent slide in second-quarter sales despite top-line growth of 16.3 percent, news of which sent the company’s share price down 3.8 percent to $56.91 at close today.
Stryker posted earnings of $309 million, or 79 cents per diluted share, on sales of $2.05 billion during the three months ended June 30. That compares with profits of $319 million, or 80 cents diluted EPS, on sales of $1.76 billion during the same period last year.
Intuitive Surgical notches another Street-beating quarter
Intuitive Surgical Inc. (NSDQ:ISRG) touted another stellar quarter and raised guidance for 2011, sending its stock up more than 6 percent to a $397.47 close today, on the way passing an all-time high-water mark of $407.00.
The Sunnyvale, Calif.-based company posted earnings of $117.4 million on $425.7 million in sales for the quarter, compared to $88.7 million on $350.7 million in sales during the same period last year. That translates into a 33 percent jump for diluted earnings per share, which rose to $2.91 from $2.19 during Q2 2010.
ICU Medical touts increased sales and revenues in Q2
ICU Medical Inc. (NSDQ:ICUI) raised its bottom end 2011 guidance to $297 to $305 million (compared to the last estimate of $295 to $305 million) after reporting a stellar quarter with increased sales and revenues.
The San Clemente, Calif.-based company posted $77.9 million in sales for the three months ended June 30, a 13 percent increase over the $68.9 million in sales during the same time last year. The quarter’s revenues amounted to $9.5 million, or 67 cents per diluted share, a nearly 20 percent increase over earnings of $7.7 million, or 56 cents per diluted share, reported last year.
“With continued strong cash flow and over $120 million of cash and investment securities and no debt, we are well positioned to invest in new and existing products, expanding our position in the I.V. therapy, critical care and oncology markets,” company CFO Scott Lamp said in the report.
ICUI stock closed at $43.62 today, nearly 2 percent over yesterday’s close at $42.82.